STAT+: Intellia says CRISPR treatment safely corrects DNA of six patients with rare disease
STAT
SEPTEMBER 16, 2022
Preliminary results from the study — just the second to show that CRISPR-based gene editing can be delivered systemically and performed in vivo, or inside the body — found that the treatment, NTLA-2002, reduced levels of the disease-causing protein, kallikrein, by 65% and 92% in the low- and high-dose cohort, respectively.
Let's personalize your content